Citations (77)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Lin-Yu Wang, Liu-Feng Liao, Cai-Lu Lei, Qiong Wu, You-Jia Guo & Yan Li. (2023) Data mining for signal detection of adverse events for taxanes based on the food and drug administration adverse drug events reporting system database. Expert Opinion on Drug Safety 22:9, pages 833-839.
Read now
Read now
Héloïse Ragelle, Fabienne Danhier, Véronique Préat, Robert Langer & Daniel G. Anderson. (2017) Nanoparticle-based drug delivery systems: a commercial and regulatory outlook as the field matures. Expert Opinion on Drug Delivery 14:7, pages 851-864.
Read now
Read now
Stephen G. Chun, Randall Hughes, Baran D. Sumer, Larry L. Myers, John M. Truelson, Saad A. Khan, Tsung-Wei Ma, Yang Xie, John S. Yordy, Susan Cooley, Jean Wu, Hak Choy & Lucien A. Nedzi. (2017) A Phase I/II Study of Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Squamous Cell Cancer of the Head and Neck. Cancer Investigation 35:1, pages 23-31.
Read now
Read now
Raffaella Palumbo, Federico Sottotetti, Giuseppe Trifirò, Elena Piazza, Antonella Ferzi, Anna Gambaro, Elena Giulia Spinapolice, Emma Pozzi, Barbara Tagliaferri, Cristina Teragni & Antonio Bernardo. (2015) Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life. Drug Design, Development and Therapy 9, pages 2189-2199.
Read now
Read now
Tarun Garg, Saurav Bhandari, Goutam Rath & Amit K. Goyal. (2015) Current strategies for targeted delivery of bio-active drug molecules in the treatment of brain tumor. Journal of Drug Targeting 23:10, pages 865-887.
Read now
Read now
Si Sun, Lichen Tang, Jian Zhang, Fangfang Lv, Zhonghua Wang, Leiping Wang, Qunling Zhang, Chunlei Zheng, Lixin Qiu, Zhen Jia, Yunhua Lu, Guangyu Liu, Zhimin Shao, Biyun Wang & Xichun Hu. (2014) Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer. International Journal of Nanomedicine 9, pages 1443-1452.
Read now
Read now
Meghna Talekar, Srinivas Reddy Boreddy, Amit Singh & Mansoor Amiji. (2014) Tumor aerobic glycolysis: new insights into therapeutic strategies with targeted delivery. Expert Opinion on Biological Therapy 14:8, pages 1145-1159.
Read now
Read now
Sara Cecco, Maria Aliberti, Paolo Baldo, Elisa Giacomin & Roberto Leone. (2014) Safety and efficacy evaluation of albumin-bound paclitaxel
. Expert Opinion on Drug Safety 13:4, pages 511-520.
Read now
Read now
Articles from other publishers (69)
Yin Liu, Lei Fan, Zhong-Hua Wang & Zhi-Ming Shao. (2023)
Nab
-paclitaxel Followed by Dose-dense Epirubicin/Cyclophosphamide in Neoadjuvant Chemotherapy for Triple-negative Breast Cancer: A Phase II Study
. The Oncologist 28:1, pages 86-e76.
Crossref
Crossref
Prashant Pandey, Dilip Kumar Arya, Mohan Kumar Ramar, Kumarappan Chidambaram & P.S. Rajinikanth. (2022) Engineered nanomaterials as an effective tool for HER2+ breast cancer therapy. Drug Discovery Today 27:9, pages 2526-2540.
Crossref
Crossref
Fei He, Jiaxuan Liu, Xin Shen, Zijing Wang, Qiao Li & Guohui Li. (2021) Adverse Event Profile for Nanoparticle Albumin-Bound Paclitaxel Compared With Solvent-Based Taxanes in Solid-Organ Tumors: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Annals of Pharmacotherapy 56:8, pages 898-909.
Crossref
Crossref
Jing Huang, Hongqi Huo, Mulan Chen, Lili Wang, Nani Li, Zhijian Huang & Lin Yang. (2022) Nanoparticle Albumin-Bound Paclitaxel is More Effective Than Paclitaxel in Experimental Endometrial Cancer. Science of Advanced Materials 14:5, pages 829-835.
Crossref
Crossref
Huixin Xu, Yue Li, Jianming Guo, Yuan Sui, Baihui Chen, Dalin Li & Jiakang Jiang. (2021) A Meta-Analysis of the Efficacy of Albumin Paclitaxel versus Docetaxel in the Treatment of Breast Cancer. Journal of Healthcare Engineering 2021, pages 1-8.
Crossref
Crossref
Dnyaneshwar Kalyane, Narendra Kumar, Neelima Anup, Kuldeep Rajpoot, Rahul Maheshwari, Pinaki Sengupta, Kiran Kalia & Rakesh Kumar Tekade. (2021) Recent advancements and future submissions of silica core-shell nanoparticles. International Journal of Pharmaceutics 609, pages 121173.
Crossref
Crossref
Xin Liu, Ningbing Ye, Chen Xiao, Xiaoxian Wang, Shiyou Li, Yihan Deng, Xiaoquan Yang, Zifu Li & Xiangliang Yang. (2021) Hyperbaric oxygen regulates tumor microenvironment and boosts commercialized nanomedicine delivery for potent eradication of cancer stem-like cells. Nano Today 40, pages 101248.
Crossref
Crossref
Muhammad Nadeem Hafeez, Christian Celia & Vilma Petrikaite. (2021) Challenges towards Targeted Drug Delivery in Cancer Nanomedicines. Processes 9:9, pages 1527.
Crossref
Crossref
Etienne J. Slapak, Lily Kong, Mouad el Mandili, Rienk Nieuwland, Alexander Kros, Maarten F. Bijlsma & C. Arnold Spek. (2021) ADAM9-Responsive Mesoporous Silica Nanoparticles for Targeted Drug Delivery in Pancreatic Cancer. Cancers 13:13, pages 3321.
Crossref
Crossref
Dong-Hui Lao, Ye Chen, Jun Fan & Jian-Zhong Zhang. (2021) Assessing taxane-associated adverse events using the FDA adverse event reporting system database. Chinese Medical Journal 134:12, pages 1471-1476.
Crossref
Crossref
Juan Gonzalez-Valdivieso, Alessandra Girotti, Jose Schneider & Francisco Javier Arias. (2021) Advanced nanomedicine and cancer: Challenges and opportunities in clinical translation. International Journal of Pharmaceutics 599, pages 120438.
Crossref
Crossref
Junji Tsurutani, Fumikata Hara, Masahiro Kitada, Masato Takahashi, Yuichiro Kikawa, Hiroaki Kato, Eiko Sakata, Yoichi Naito, Yoshie Hasegawa, Tsuyoshi Saito, Tsutomu Iwasa, Naruto Taira, Tsutomu Takashima, Kosuke Kashiwabara, Tomohiko Aihara & Hirofumi Mukai. (2021) Randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer. The Breast 55, pages 63-68.
Crossref
Crossref
Shigeyuki Tamura, Hirokazu Taniguchi, Kazuhiro Nishikawa, Hiroshi Imamura, Junya Fujita, Atsushi Takeno, Jin Matsuyama, Yutaka Kimura, Junji Kawada, Motohiro Hirao, Masashi Hirota, Kazumasa Fujitani, Yukinori Kurokawa, Daisuke Sakai, Hisato Kawakami, Toshio Shimokawa & Taroh Satoh. (2020) A phase II trial of dose-reduced nab-paclitaxel for patients with previously treated, advanced or recurrent gastric cancer (OGSG 1302). International Journal of Clinical Oncology 25:12, pages 2035-2043.
Crossref
Crossref
Mahendra Kumar Prajapati, Aniketh Bishnu, Pritha Ray & Pradeep R. Vavia. (2019) Selectivity Enhancement of Paclitaxel Liposome Towards Folate Receptor-Positive Tumor Cells by Ligand Number Optimization Approach. AAPS PharmSciTech 20:8.
Crossref
Crossref
Yongjia Liu, Fengren Wu, Yongle Ding, Bangshang Zhu, Yue Su & Xinyuan Zhu. (2019) Preparation and Characterization of Paclitaxel/Chitosan Nanosuspensions for Drug Delivery System and Cytotoxicity Evaluation In Vitro. Advanced Fiber Materials 1:2, pages 152-162.
Crossref
Crossref
Xin Li & Hyungju Kwon. (2019) Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Elderly Patients with Metastatic Breast Cancer: A Meta-Analysis. Journal of Clinical Medicine 8:10, pages 1689.
Crossref
Crossref
Archana George, Priyanka A. Shah & Pranav S. Shrivastav. (2019) Natural biodegradable polymers based nano-formulations for drug delivery: A review. International Journal of Pharmaceutics 561, pages 244-264.
Crossref
Crossref
Peng Dong, K.P. Rakesh, H.M. Manukumar, Yasser Hussein Eissa Mohammed, C.S. Karthik, S. Sumathi, P. Mallu & Hua-Li Qin. (2019) Innovative nano-carriers in anticancer drug delivery-a comprehensive review. Bioorganic Chemistry 85, pages 325-336.
Crossref
Crossref
Qingmei Li, Hong Zhang, Xiaoxue Zhu, Chengjiao Liu, Min Wu, Cuiyun Li, Xiaojiao Li, Lei Gao & Yanhua Ding. (2018) Tolerance, Variability and Pharmacokinetics of Albumin-Bound Paclitaxel in Chinese Breast Cancer Patients. Frontiers in Pharmacology 9.
Crossref
Crossref
Feng Li, Huixia Zhang, Miao He, Jinhui Liao, Nianhang Chen, Yan Li, Simon Zhou, Maria Palmisano, Alex Yu, Manjunath P. Pai, Hebao Yuan & Duxin Sun. (2018) Different Nanoformulations Alter the Tissue Distribution of Paclitaxel, Which Aligns with Reported Distinct Efficacy and Safety Profiles. Molecular Pharmaceutics 15:10, pages 4505-4516.
Crossref
Crossref
Ana C. Gregório, Manuela Lacerda, Paulo Figueiredo, Sérgio Simões, Sérgio Dias & João Nuno Moreira. (2018) Meeting the needs of breast cancer: A nucleolin’s perspective. Critical Reviews in Oncology/Hematology 125, pages 89-101.
Crossref
Crossref
Mohammad M. Kamal & Sami Nazzal. (2018) Novel sulforaphane-enabled self-microemulsifying delivery systems (SFN-SMEDDS) of taxanes: Formulation development and in vitro cytotoxicity against breast cancer cells. International Journal of Pharmaceutics 536:1, pages 187-198.
Crossref
Crossref
Adrienne G. Waks & Eric P. Winer. 2018. The Breast. The Breast
885
906.e8
.
Yun Liu, Guoxin Ye, Dali Yan, Lei Zhang, Fan Fan & Jifeng Feng. (2017) Role of nab-paclitaxel in metastatic breast cancer: a meta-analysis of randomized clinical trials. Oncotarget 8:42, pages 72950-72958.
Crossref
Crossref
Joseph D. Tariman. (2017) Changes in Cancer Treatment. Nursing Clinics of North America 52:1, pages 65-81.
Crossref
Crossref
F. Danhier. (2016) To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine?. Journal of Controlled Release 244, pages 108-121.
Crossref
Crossref
Raffaella Palumbo, Federico Sottotetti & Antonio Bernardo. (2016)
Targeted chemotherapy with nanoparticle albumin-bound paclitaxel (
nab
-paclitaxel) in metastatic breast cancer: which benefit for which patients?
. Therapeutic Advances in Medical Oncology 8:3, pages 209-229.
Crossref
Crossref
Paul D. Schmitt, Niraj S. Trasi, Lynne S. Taylor & Garth J. Simpson. (2015) Finding the Needle in the Haystack: Characterization of Trace Crystallinity in a Commercial Formulation of Paclitaxel Protein-Bound Particles by Raman Spectroscopy Enabled by Second Harmonic Generation Microscopy. Molecular Pharmaceutics 12:7, pages 2378-2383.
Crossref
Crossref
Lars M. Wagner, Hong Yin, David Eaves, Mark Currier & Timothy P. Cripe. (2014) Preclinical evaluation of nanoparticle albumin-bound paclitaxel for treatment of pediatric bone sarcoma. Pediatric Blood & Cancer 61:11, pages 2096-2098.
Crossref
Crossref
H.H. Loong, E. Winquist, J. Waldron, E.X. Chen, J. Kim, D. Palma, N. Read, A.R.A. Razak, I. Diaz-Padilla, K. Chan, A. Bayley, M. Hossain, L. Wang, S. Chin, L.L. Siu & A. Hope. (2014) Phase 1 study of nab-paclitaxel, cisplatin and 5-fluorouracil as induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced squamous cell carcinoma of the oropharynx. European Journal of Cancer 50:13, pages 2263-2270.
Crossref
Crossref
Roshan Karki, Brandon-Luke L. Seagle, Wilberto Nieves-Neira & Shohreh Shahabi. (2014) Taxanes in combination with biologic agents for ovarian and breast cancers. Anti-Cancer Drugs 25:5, pages 536-554.
Crossref
Crossref
Huile Gao, Shilei Cao, Chen Chen, Shijie Cao, Zhi Yang, Zhiqing Pang, Zhangjie Xi, Shuaiqi Pan, Qizhi Zhang & Xinguo Jiang. (2013) Incorporation of lapatinib into lipoprotein-like nanoparticles with enhanced water solubility and anti-tumor effect in breast cancer. Nanomedicine 8:9, pages 1429-1442.
Crossref
Crossref
Vasiliki Nikolaou, Alexander Stratigos, Dimitrios Bafaloukos & Andreas Katsambas. (2013) Antiangiogenic and antiapoptotic treatment in advanced melanoma. Clinics in Dermatology 31:3, pages 257-263.
Crossref
Crossref
David S. Alberts, John A. Blessing, Lisa M. Landrum, David P. Warshal, Lainie P. Martin, Stephen L. Rose, Albert J. Bonebrake & Lois M. Ramondetta. (2012) Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: A gynecologic oncology group study. Gynecologic Oncology 127:3, pages 451-455.
Crossref
Crossref
Jun Qi, Jielu Zhao & David G. I. Kingston. 2012. Plant Bioactives and Drug Discovery. Plant Bioactives and Drug Discovery
263
336
.
Stavros Peroukides, Alexandros Alexopoulos, Haralabos Kalofonos & Helen Papadaki. (2012) Cardiovascular effects of treatment with taxanes. Journal of Cardiovascular Medicine 13:5, pages 319-324.
Crossref
Crossref
Zsóka Weiszhár, Judit Czúcz, Csaba Révész, László Rosivall, János Szebeni & Zoltán Rozsnyay. (2012) Complement activation by polyethoxylated pharmaceutical surfactants: Cremophor-EL, Tween-80 and Tween-20. European Journal of Pharmaceutical Sciences 45:4, pages 492-498.
Crossref
Crossref
Paul F. Richardson. 2012. Annual Reports in Medicinal Chemistry Volume 47. Annual Reports in Medicinal Chemistry Volume 47
239
252
.
John Pippen, Devchand Paul, Svetislava Vukelja, Alicia Clawson & Jose Iglesias. (2011) Dose-dense doxorubicin and cyclophosphamide followed by dose-dense albumin-bound paclitaxel plus bevacizumab is safe as adjuvant therapy in patients with early stage breast cancer. Breast Cancer Research and Treatment 130:3, pages 825-831.
Crossref
Crossref
Shunzi Li, Bethany Powell Gray, Michael J. McGuire & Kathlynn C. Brown. (2011) Synthesis and biological evaluation of a peptide–paclitaxel conjugate which targets the integrin αvβ6. Bioorganic & Medicinal Chemistry 19:18, pages 5480-5489.
Crossref
Crossref
Robert L. Coleman, William E. Brady, D. Scott McMeekin, Peter G. Rose, John T. Soper, Samuel S. Lentz, James S. Hoffman & Mark S. Shahin. (2011) A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A Gynecologic Oncology Group Study. Gynecologic Oncology 122:1, pages 111-115.
Crossref
Crossref
Matthias Wacker, Anja Zensi, Jürgen Kufleitner, Aaron Ruff, Jessica Schütz, Tobias Stockburger, Thomas Marstaller & Vitali Vogel. (2011) A toolbox for the upscaling of ethanolic human serum albumin (HSA) desolvation. International Journal of Pharmaceutics 414:1-2, pages 225-232.
Crossref
Crossref
Jay Prakash Jain, Wubeante Yenet Ayen, Abraham J. Domb & Neeraj Kumar. 2011. Biodegradable Polymers in Clinical Use and Clinical Development. Biodegradable Polymers in Clinical Use and Clinical Development
1
58
.
Lisa D. Volk, Michael J. Flister, Deena Chihade, Neil Desai, Vuong Trieu & Sophia Ran. (2011) Synergy of Nab-paclitaxel and Bevacizumab in Eradicating Large Orthotopic Breast Tumors and Preexisting Metastases. Neoplasia 13:4, pages 327-IN14.
Crossref
Crossref
Joel Richard. (2011) Challenges and opportunities in the delivery of cancer therapeutics. Therapeutic Delivery 2:1, pages 107-121.
Crossref
Crossref
Marites P. Melancon & Chun Li. (2011)
Multifunctional Synthetic Poly(
l
-Glutamic Acid)–Based Cancer Therapeutic and Imaging Agents
. Molecular Imaging 10:1, pages 7290.2011.00007.
Crossref
Crossref
Nicholas Robert, Lea Krekow, Chris Stokoe, Alicia Clawson, Jose Iglesias & Joyce O’Shaughnessy. (2010) Adjuvant dose-dense doxorubicin plus cyclophosphamide followed by dose-dense nab-paclitaxel is safe in women with early-stage breast cancer: a pilot study. Breast Cancer Research and Treatment 125:1, pages 115-120.
Crossref
Crossref
Stacy L. Moulder. (2010) Novel Cytotoxic Backbones and Targeted Therapies: Recent Data and Ongoing Clinical Trials. Clinical Breast Cancer 10, pages S30-S40.
Crossref
Crossref
Patricia R. Blank, Konstantin J. Dedes & Thomas D. Szucs. (2010) Cost Effectiveness of Cytotoxic and Targeted Therapy for Metastatic Breast Cancer. PharmacoEconomics 28:8, pages 629-647.
Crossref
Crossref
Savita Bisht, Masamichi Mizuma, Georg Feldmann, Niki A. Ottenhof, Seung-Mo Hong, Dipankar Pramanik, Venugopal Chenna, Collins Karikari, Rajni Sharma, Michael G. Goggins, Michelle A. Rudek, Rajani Ravi, Amarnath Maitra & Anirban Maitra. (2010) Systemic Administration of Polymeric Nanoparticle-Encapsulated Curcumin (NanoCurc) Blocks Tumor Growth and Metastases in Preclinical Models of Pancreatic Cancer. Molecular Cancer Therapeutics 9:8, pages 2255-2264.
Crossref
Crossref
Ralph J. Passarella, Daniel E. Spratt, Alice E. van der Ende, John G. Phillips, Hongmei Wu, Vasanth Sathiyakumar, Li Zhou, Dennis E. Hallahan, Eva Harth & Roberto Diaz. (2010) Targeted Nanoparticles That Deliver a Sustained, Specific Release of Paclitaxel to Irradiated Tumors. Cancer Research 70:11, pages 4550-4559.
Crossref
Crossref
Mauro Ferrari. (2010) Frontiers in cancer nanomedicine: directing mass transport through biological barriers. Trends in Biotechnology 28:4, pages 181-188.
Crossref
Crossref
Denise A. Yardley. (2010) Visceral Disease in Patients With Metastatic Breast Cancer: Efficacy and Safety of Treatment With Ixabepilone and Other Chemotherapeutic Agents. Clinical Breast Cancer 10:1, pages 64-73.
Crossref
Crossref
Yolanda Fernández, Juan Cueva, Andrés G. Palomo, Manuel Ramos, Ana de Juan, Lourdes Calvo, Jesús García-Mata, Paula García-Teijido, Ignacio Peláez & Laura García-Estévez. (2010) Novel therapeutic approaches to the treatment of metastatic breast cancer. Cancer Treatment Reviews 36:1, pages 33-42.
Crossref
Crossref
George Dranitsaris, Robert Coleman & William Gradishar. (2009) nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial. Breast Cancer Research and Treatment 119:3, pages 717-724.
Crossref
Crossref
Tejal A. Patel & Edith A. Perez. 2010. Management of Breast Diseases. Management of Breast Diseases
425
449
.
Leslie S. Kurtzberg, Stephanie D. Roth, Rebecca G. Bagley, Cecile Rouleau, Min Yao, Jennifer L. Crawford, Roy D. Krumbholz, Steven M. Schmid & Beverly A. Teicher. (2009) Bone marrow CFU-GM and human tumor xenograft efficacy of three tubulin binding agents. Cancer Chemotherapy and Pharmacology 64:5, pages 1029-1038.
Crossref
Crossref
William J. GradisharDimitry KrasnojonSergey CheporovAnatoly N. MakhsonGeorgiy M. ManikhasAlicia ClawsonPaul Bhar. (2009)
Significantly Longer Progression-Free Survival With
nab
-Paclitaxel Compared With Docetaxel As First-Line Therapy for Metastatic Breast Cancer
. Journal of Clinical Oncology 27:22, pages 3611-3619.
Crossref
Crossref
David G. I. Kingston. (2009) Tubulin-Interactive Natural Products as Anticancer Agents. Journal of Natural Products 72:3, pages 507-515.
Crossref
Crossref
Julie Gold & Eric P. Winer. 2009. The Breast. The Breast
1233
1261
.
Sarah A. Holstein & Raymond J. Hohl. 2009. Pharmacology and Therapeutics. Pharmacology and Therapeutics
83
90
.
Savita Bisht, Georg Feldmann, Jan-Bart M. Koorstra, Michael Mullendore, Hector Alvarez, Collins Karikari, Michelle A. Rudek, Carlton K. Lee, Amarnath Maitra & Anirban Maitra. (2008)
In vivo
characterization of a polymeric nanoparticle platform with potential oral drug delivery capabilities
. Molecular Cancer Therapeutics 7:12, pages 3878-3888.
Crossref
Crossref
Mark E. Davis, Zhuo Chen & Dong M. Shin. (2008) Nanoparticle therapeutics: an emerging treatment modality for cancer. Nature Reviews Drug Discovery 7:9, pages 771-782.
Crossref
Crossref
Matti S. Aapro & Gunter Von Minckwitz. (2008) Molecular basis for the development of novel taxanes in the treatment of metastatic breast cancer. European Journal of Cancer Supplements 6:10, pages 3-11.
Crossref
Crossref
Lisa D. Volk, Michael J. Flister, Christopher M. Bivens, Alan Stutzman, Neil Desai, Vuong Trieu & Sophia Ran. (2008) Nab-paclitaxel Efficacy in the Orthotopic Model of Human Breast Cancer Is Significantly Enhanced By Concurrent Anti–Vascular Endothelial Growth Factor A Therapy. Neoplasia 10:6, pages 613-623.
Crossref
Crossref
Beverly A. Teicher. (2008) Newer Cytotoxic Agents: Attacking Cancer Broadly. Clinical Cancer Research 14:6, pages 1610-1617.
Crossref
Crossref
Francesca Leonelli, Angela La Bella, Luisa Migneco & Rinaldo Bettolo. (2008) Design, Synthesis and Applications of Hyaluronic Acid-Paclitaxel Bioconjugates†. Molecules 13:2, pages 360-378.
Crossref
Crossref
. (2008) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 17:2.
Crossref
Crossref
S Moulder & GN Hortobagyi. (2007) Advances in the Treatment of Breast Cancer. Clinical Pharmacology & Therapeutics 83:1, pages 26-36.
Crossref
Crossref